Filtering by:
ImmunotherapyPanel Backs CAR T-cell Therapy for Leukemia: What You Need to Know and What’s Next
The US and Drug Administration (FDA) this week convened a panel of outside experts to weigh in on the readiness of a first-of-its-kind cancer treatment called CAR T-cell therapy. The panel unanimously recommended that the agency approve the treatment. What does this mean for patients? And is CAR T-cell therapy going to play an increasing role in cancer treatment in general? In this interview, Leonard Lichtenfeld, MD, MACP, American Cancer Society deputy chief medical officer, gives us his take.
FDA Approves Keytruda (Pembrolizumab) for Any Tumor with Specific Genetic Change
The US Food and Drug Administration (FDA) has expanded the approval of the immunotherapy drug Keytruda (pembrolizumab) to include tumors with a specific genetic change regardless of cancer type.
Melanoma Survivor Finds Hope Through Immunotherapy
When Bryant Wieneke started feeling “funky” in April 2016, he figured it was just part of getting older. A urine test revealed abnormal cells, which led to more testing and eventually, a diagnosis of advanced melanoma skin cancer.
FDA Approves Bavencio (Avelumab) for Bladder Cancer
The US Food and Drug Administration (FDA) has approved the immunotherapy drug Bavencio (avelumab) to treat people with advanced urothelial carcinoma, the most common type of bladder cancer.